HIV mutation literature information.


  HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon.
 PMID: 30871487       2019       BMC infectious diseases
Abstract: Thymidine-analogue mutations (TAMs)-1 [T215FY (46.53%), M41 L (22.77%), L210 W (8.91%)], with cross-resistance to AZT and TDF, were higher compared to TAMs-2 [D67N (21.78%), K70R (19.80%), K219QE (18.81%)].
Result: Of note, TAMs-1 were predominant (T215F/Y: 46.5%; M41 L: 22.8%; L210 W: 8.9%) and associated with higher levels of resistance to both AZT and TDF; as compared to TAMs-2 that had relatively lower prevalence (D67N: 21.8%; K70R: 19.8%; K219Q/E: 18.8%) and were associated preferentially with AZT/D4T-resistance.


  Two Coselected Distal Mutations in HIV-1 Reverse Transcriptase (RT) Alter Susceptibility to Nonnucleoside RT Inhibitors and Nucleoside Analogs.
 PMID: 30894467       2019       Journal of virology
Discussion: The primary resistance mutations to AZT are T215F/Y and/or K70R.


  Prevalence of drug resistance mutations among ART-naive and -experienced HIV-infected patients in Sierra Leone.
 PMID: 30989237       2019       The Journal of antimicrobial chemotherapy
Abstract: The most prevalent RAMs were K103N (40.7%), M184V (28.8%), D67N (15.3%) and T215I/F/Y (15.3%).
Result: The most prevalent RT RAMs were as follows: K103N (n = 24, 40.7%), M184V (n = 17, 28.8%), D67N (n = 9, 15.3%), T215I/F/Y (n = 9, 15.3%) and M41L (n = 7, 11.9%) (Figure 1).


  HIV Drug Resistance Mutations in Patients with HIV and HIV-TB Coinfection After Failure of First-Line Therapy: A Prevalence Study in a Resource-Limited Setting.
 PMID: 31117863       2019       Journal of the International Association of Providers of AIDS Care
Table: T215Y


  Antiretroviral drug resistance mutations among patients failing first-line treatment in Hanoi, Vietnam.
 PMID: 31190911       2019       Infection and drug resistance
Table: T215Y
Discussion: TAMs occur in different patterns: type 1 includes M41L, L210W and T215Y (14%, 11.6% and 4.7% prevalence, respectively, in our study), and type 2 includes K70R, D67N T215F and K219Q/E (37.2%, 27.9%, 27.9% and 14% prevalence, respectively, in our study).
Discussion: The accumulation of other mutations observed included TAMs (including M41L, L210W, T215Y, K70R, D67N, T215F and K219Q), resulting in increased resistance to AZT, TDF,


  Analysis of generalized semiparametric mixed varying-coefficients models for longitudinal data.
 PMID: 31827312       2019       The Canadian journal of statistics
Introduction: ACTG 244 enrolled HIV-infected patients receiving zidovudine (ZDV) monotherapy, and monitored them every eight weeks for occurrence of the 215 (T215Y/F) ZDV resistance mutation.
Introduction: ACTG 244 enrolled HIV-infected patients taking zidovudine (ZDV) monotherapy and monitored their HIV in plasma every eight weeks for presence of the T215Y/F ZDV resistance mutation.
Introduction: In conclusion, switching to the combination therapies based on the T215Y mutation has positive benefits as compared to continuing with ZDV monotherapy ZDV even after drug-resistant virus was detected.


  Genetic diversity and antiretroviral resistance-associated mutation profile of treated and naive HIV-1 infected patients from the Northwest and Southwest regions of Cameroon.
 PMID: 31751428       2019       PloS one
Result: Eleven (25%, 11/44) of the RTRM were thymidine analogue mutations (T215FY [2.5%, 6/239], K70R [1.7%, 4/239] and 0.8% (2/239) each of D67N, L210W, M41L, and K219Q/E (Fig 2).
Result: The mutational pattern, D67N-M41L-M184V-L210W-T215F/Y was
Table: T215F/Y


  Analysis of HIV-1 diversity, primary drug resistance and transmission networks in Croatia.
 PMID: 31754119       2019       Scientific reports
Result: The sequence originating from the UK had a similar mutation pattern with additional SDRMs (PI: M46L, V82A and NRTI: T215Y).
Discussion: Phylogenetic inference indicated a transmission link with one UK sequence with a similar mutation pattern, PI: V32I, M46L, I47A, V82A + NRTI: T215Y + NNRTI: L100I, K103N.
Discussion: These variants develop from strains containing T215Y/F mutations, primarily selected under


  Sustained virological response and drug resistance among female sex workers living with HIV on antiretroviral therapy in Kampala, Uganda: a cross-sectional study.
 PMID: 31266818       2019       Sexually transmitted infections
Table: T215Y


  Elucidating molecular interactions of L-nucleotides with HIV-1 reverse transcriptase and mechanism of M184V-caused drug resistance.
 PMID: 31872074       2019       Communications biology
Discussion: It was reported that (+)-FTC selects for T215Y as opposed to M184V in cell culture.



Browser Board

 Co-occurred Entities




   Filtrator